Trials / Completed
CompletedNCT00138749
An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The Treatment Of Stress Urinary Incontinence (SUI) In Women.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 402 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SS-RBX |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-08-30
- Last updated
- 2011-04-07
Locations
95 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00138749. Inclusion in this directory is not an endorsement.